

Sheet 1 of 7

Form PTO-1449  INFORMATION: DISCLOSURE CITATION			Docket No. Application No. EMU108DIV(1) 08/488,097					
			Applicant: Dennis C. Liotta, et al.					
	AN APPLI			7, 1995	Group A 1205	Group Art Unit		
				NT DOCUMENTS				
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate	
KWI	AA	5,587,480	12/24/96	Belleau, et al.	544	310		
KW	AB	5,539,116	07/23/96	Liotta and Choi	544	317		
EW	AC	5,532,246	07/02/96	Belleau, et al.	514	274		
FW	AD	5,486,520	01/23/96	Belleau, et al.	514	274		
KW	AE	5,466,806	11/14/95	Belleau, et al.	544	310		
KW.	AF	5,444,063	08/22/95	Schinazi	514	262		
KW.	AG	5,276,151	01/04/94	Liotta	544	317		
EW	AH	5,270,315	12/14/93	Belleau, et al.	514	262		
KW	Al	5,248,776	09/28/93	Chu, et al.	544	310	_	
+W	AJ	5,234,913	08/10/93	Furman, Jr., et	514	49		
KIN	AK	5,210,085	05/11/93	Liotta, et al.	514	274		
TEW	AL	5,204,466	04/20/93	Liotta, et al.	544	317		
EW	AM	5,185,437	02/09/93	Koszalka, et al.	536	24		
PW	AN	5,179,104	01/12/93	Chu, et al.	544	310		
W I	AO	5,071,983	12/10/91	Koszalka, et al.	544	317		
, KM	AP	5,059,690	10/22/91	Zahler, et al.	544	276		
KW.	AQ	5,047,407	09/10/91	Belleau, et al.	514	274		
KW	AR	5,041,449	08/20/91	Belleau, et al.	514	274	-	
KW	AS	5,011,774	04/30/91	Farina, et al.	435	87		
KW	AT	4,963,533	10/16/90	de Clercq, et al.	514	49		
KW	AU	4,916,122	04/10/90	Chu, et al.	514	50		
KW	AV	4,900,828	02/13/90	Belica, et al.	544	317		
KW	AW	4,879,277	11/07/89	Mitsuya, et al.	514	49		
KW	AX	4,861,759	08/29/89		514	46		
KW	AY	4,336,381	06/22/82	Nagata, et al.	544	313		
KW	AZ	4,000,137	12/28/76	Dvonch, et al.	260	252		
KM	AAA	07/686,617	07/02/96	Cheng, et al.		-		
KW.	AAB	07/718,806	06/21/91	Cheng				
KW	AAC	07/785,545	10/31/91	Cheng				
Examiner:		1 Wong		Considered:				
		tation considered, whe not considered. Include		on is in conformance with N			h citation if	

340639

Sheet 2 of 7

Form PTO-1449			Doc	ket No.: EMU108	Application No. 08/488,097						
INFORM	ATION DISC	CLOSURE	Applicant: Dennis C. Liotta, et al.								
IN:AN APPLICATION (Use several sheets if necessary)			Filing Date: June 7, 1995			Group Art Unit 1205					
			FOREIGN PATENT DOCUMENTS								
		Document Num	oer.	Date	Country	, c	lass	Subclass	YES	NO	
KW.	BA	WO94/1480	)2	07/07/94	PCT		<b></b>	_			
KIN	BB	WO94/0979	)3	05/11/94	PCT			~		-	
KIN	BC	WO94/0415	54	03/04/94	PCT			_			
KW.	/ BD	WO92/2167	76	12/10/92	PCT						
KW	BE	WO92/1851	17	10/29/92	PCT			-,		-	
KW	/ BF	WO92/1530	) <b>9</b> \	09/17/92	PCT						
KW	√ BG	WO92/1530	<b>)8</b>	09/17/92	PCT						
KW	BH	WO92/1474	13	09/03/92	PCT			-		-	
KW	` Bl	WO92/1472	29	09/03/92	PCT		_	(			
KW	BJ	WO92/1049	7	06/25/92	PCT						
EW	/ BK	WO92/1049	96	06/25/92	PCT			(			
KW	/ BL	WO92/0872	27	05/29/92	PCT						
KW	ВМ	WO91/1715	<b>59</b> \	11/14/91	PCT			1			
KW.	BN	WO91/1118	36	08/08/91	PCT			1			
KIN	ВО	WO90/1202	23	10/18/90	PCT						
KW/	BP	WO88/0753	32	10/06/88	PCT						
			·								
•		٠.									
		,									
	_			-							
	-										
Examiner:		Nong		Date Co	nsidered:	102	198				
EXAMINER: I	nitial if citati	on considered, wh	ethe	er or not citation is	s in conforman	ce with M	IPEP § 609; C	Draw line throu	ugh citati	on if	

340639

Sheet 3 of 7

Form PTO-1449			ocket No. E	MU108	DIV(1)		Application No 08/488,097				
INFORMATION DISCLOSURE CITATION			Applicant: Dennis C. Liotta, <i>et al.</i>								
	IN AN APPLICATION (Use several sheets if necessary)			Filing:Date: June 7, 1995			Jnit				
	F			NT DOCUMENT	CUMENTS						
		Document Number	r Date		Country	Class	Subclass	YES	NO		
KW.	CA	0 526 253	02/03	3/93	Europe						
KV.	CB	0 515 157	11/2	5/92	Europe		~				
KW	/ CC	0 515 156	11/2	5/92	Europe		_				
KW	CD	0 515 144	11/2	5/92	Europe		_				
XW	/ CE	0 494 119	07/0	8/92	Europe						
KW	CF	0 433 898	08/1	6/90	Europe						
KW.	CG	0 382 526	06/2	7/90	Europe						
KINI	СН	0 375 329	01/24	4/90	Europe						
KW.	CI	0 361 831	04/04	4/90	Europe						
KW.	CJ	0 337 713	10/12	2/88	Europe						
KW.	СК	0 217 580	04/08	8/87	Europe		~				
FW.	CL	8901258	12/1	7/90	Netherland						
KW/	CM	07109221	04/2	5/95	Japan						
KW.	CN	2-69469	03/08	3/90	Japan						
KW,	СО	2-69476`	03/08	<b>3/90</b>	Japan						
	<del>CP</del>	<del>73004/91</del>			Australia -						
KM	CQ	630913	09/03	3/92	Australia						
KW	~ CR	665187	02/20	0/92	Australia						
KW.	∨ CS	238017	06/2'	7/94	New Zaalan						
KW.	CT	421 636	04/10	0/91	Europe						
FW.	CU	357 009	03/0'	7/90	Europe						
KM.	CV	350 811	01/1'	7/90	Europe	~					
									,		
	<del>78</del> 2										
	,										
			1								
Examiner:	K. W	ma		Date Cor	0/	102/93					
EXAMINER:	Initial if citation	on considered, whe	her or not	citation is	in conformance with next communic	th MPEP § 609; I	Oraw line thro cant.	ugh citati	on if		

\* Copy not provided.





Sheet 4 of 7

					neet 4 of /			
Form PTO-	1449		Docket No: EMU108DIV(1)	Application No. 08/488,097				
INFORM	ATION CITA	DISCLOSURE	Applicant: Dennis C. Liotta, <i>et al.</i>					
	N APP	LICATION ets if necessary)	Filing Date: June 7, 1995	Group Art Unit				
			UMENTS (Including Author, Title, Date, Pertin					
KM	DA	Abobo, et al., "Pharmacokinetics of 2',3'-Dideoxy-5-fluoro-3'-thiacytidine in Rats," J. of Pharmaceutical Sciences, 83(1):96-99 (1994)						
KN	DB		iedermann, "Intellectual Property and Chi f Racemic Drugs in a Racemic Switch Scen (7/2/96)	•				
	DC		al., "Potent and Selective Anti-HTLV-III/					
KW1		Dideoxycytidin	ene, the 2',3'-Unsaturated Derivative of 2',	3'-Dideoxycytidine,'	'			
		Biochemical an	d Biophysical Research Communications, 1	40(2): 735-742 (1986	)			
FW-	DD	-	., "The enantiomers of 1.betaadenyl-2.alp		•			
[W]			l)cyclobutane," Tetrahedron: Asymmetry, 3					
KM,	DE	Against HIV-1, 1989	d., "Design and Activity of a Novel Class of "International Conference on AIDS, Mont	real, Quebec, Canad	a, June 4-9,			
XW.	DF	Borthwick, et al., "Synthesis and Enzymatic Resolution of Carbocyclic 2'-Ara-Fluoro-Guanosine: A Potent New Anti-Herpetic Agent," J. Chem. Soc. Commun., Vol. 10. pp. 656-658 (1988)						
KW	DG	Carter, et al., "Activities of (-)-Carbovir and 3'-Azido-3'-Deoxythymidine Against Human Immunodeficiency Virus In Vitro," Antimicrobial Agents and Chemotherapy, 34(6):1297-1300 (1990)						
•	DH		Neng, et al., "Deoxycytidine Deaminase-res					
<del>KM</del> -		, , ,	3'-Dideoxy-3'-thiacytidine in the Inhibition	<del>-</del>				
			he Journal of Biological Chemistry, 267(20					
th =	Di	Chu, C.K., et al., "An Efficient Total Synthesis of 3'-Azido-3'-Deoxythiymidine (AZT) and 3'-Azido-2',3'-Dideoxyuridine (AZDDU, CS-87) from D-Mannitol," Tetrahedron Lett., 29(42):5349-5352 (1988)						
10.1.	DJ		omparative Activity of 2',3'-Saturated and					
kn 1			ides Against Human Immunodeficiency Vi Cells,'' <i>Biochem. Pharm.</i> , 37(19):3543-3548		eral Blood			
, 4	DK		ructure-Activity Relationships of Pyrimidi					
KW	'		nan Immunodeficiency Virus Type 1 in Per	ripheral Blood Mono	nuclear			
\ \		Cells," J. Med. Chem.; 32:612 (1989)						
	DL		, "Evaluation of the Potent Anti-Hepatitis					
K4/			nethyl)-1,3-Oxathiolan-5-yl]Cytosine in a I I <i>gents and Chemotherapy</i> , 616-619 (1992)	novel in Vivo Model	,"			
	<b></b>							
KMS	DM	Connolly and Hammer, "Minireview: Antiretroviral Therapy: Reverse Transcriptase Inhibition," Antimicrobial Agents and Chemotherapy, 36(2):245-254 (1992)						
1/1/	DN		al., "Catabolism of 3'-Azido-3'-Deoxythym					
1 / v /			ith Evidence of Formation of 3'-Amino-3'-					
		Catabolite for	Human Bone Marrow Cells," <i>Molecuilar P</i>	harmacology, 39:258	3-266 (1991)			
<u> </u>		<u>L</u>	L Data Constitution					
Examiner:	K.	Wong	Date Considered: 01 62	198				
EXAMINER not in confo	EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

	•		Sheet 5 of 7						
Form PTO-1449		Docket No: EMU108DIV(1)	Application No 08/488,097						
	N DISCLOSURE ATION	Applicant Dennis C. Liotta, <i>et al.</i>							
	PPLICATION heets if necessary)	Filing Date: June 7, 1995	Group Art Unit 1205						
		MENTS (Including Author, Title, Date							
FW EA	and Interactio Chemotherapy	ns with Probenecid in Rhesus Mon , 35(5):801-807 (1991)	_						
KW/ EB			cation of Hepatitis B Virus in vitro by gues," Natl. Acad. Sci. USA, 88:8495-						
XW EC		"Prevention of activation of HIV-1 a. & Chemotherapy, 4(1):55-63 (1993)	by antiviral agents in OM-10.1 cells," 3)						
ED			ility, and Metabolic Disposition in Rats						
V1.			thiolan-5-yl] Cytosine, a Nucleoside						
~V'		against Human Immunodeficiency							
		Antimicrobial Agents and Chemotherapy, 37(11):2285-2292 (1993)							
EE		, "The Anti-Hepatitis B Virus Activ							
KM		(-) and (+) Enantiomers of cis-5-Flu							
		yıjCytosine," Antimicrobiai Agenis i	and Chemotherapy, 36(12):2686-2692						
VI. EF	(1992)	al "Desolution of Aristoromygin F	Chantiomers," J. Med. Chem., 1985,						
KW 7 Er	Vol. 28, 1385-1	•	mantiomers, J. Med. Chem., 1965,						
EG			e Preparation of Pure Enantiomers of						
KIN / LO		Hoong, et al., "Enzyme-Mediated Enantioselective Preparation of Pure Enantiomers of the Antiviral Agent 2',3'-Dideoxy-5-fluoro-3'-thiacytidine (FTC) and Related							
( 0 )		Compounds," J. Org. Chem., 57:5563-5565 (1992)							
C EH		Ito, et al., "Chirally Selective Synthesis of Sugar Moiety of Nucleosides by							
KINA		Chemicoenzymatic Approach: L- and D-Riboses, Showdomycin, and Cordycepin," J.							
	_	c., 103:6739-6741 (1981)							
( EI	Jansen, et al.,	High-Capacity In Vitro Assessmen	nt of Anti-Hepatitis B Virus Compound						
KHH	Selectivity by	a Virion-Specific Polymerase Chain	Reaction Assay," Antimicrobial						
		emotherapy, 441-447 (1993)							
(d \ EJ			ogical Evaluation of β-L-(2R,5S)- and						
KMY	' '	•	rine Nucleosides and Potential Anti-						
		J. Med. Chem., 36(2):181-195 (1993							
NYEK			bonucleosides of Some Pyrimidines:						
<u> </u>		Biological Activities," J. Med. Chen							
KY O EL	Research, 97:1	39-146 (1981)	e D-arabinonucleosides," Carbohydrate						
[/   EM	, ,	tent and Selective In Vitro Activity	•						
KM		* *.	n Immunodeficiency Virus," Biochem.						
		):2713-2718 (1987)	Call Day (AID 1) At 1						
EN	Manmoudian,	et al., "Enzymatic Production of O	ptically Pure (2'R-cis)-2'-deoxy-3'- HIV Agent," Enzyme Microb. Technol.,						
KM-		93, Vol. 15, 749-755, published by the							
<del></del>	September 19	75, voi. 15, 145-155, published by th	iic Giaxo Group Research						
EXAMINER: Initi	al if citation considered	whether or not citation is in conformance	with MPEP § 609; Draw line through citation if						
		Include copy of this form with next commu							
	7								

K. Wong

1/02/97

34063

d

Sheet 6 of 7

Form PTO-1449			Docket No.:	Application No.					
101111110-	1440		EMU108DIV(1) Applicant:	08/488,097					
INFORMATION DISCLOSURE CITATION			Dennis C. Liotta, et al.						
IN AN APPLICATION (Use several sheets if necessary)			Filing Date: June 7, 1995	Group Art Unit 1205					
				-					
		OTHER DOCU	MENTS (Including Author, Title, Date, Pertin	ent Pages, Etc.)					
1	FA		tal., "3'-Azido-3'-Deoxythymidine (BW A						
101			ne Infectivity and Cytopathic Effect of Hu	,					
FW-		Type III/Lymphadenopathy-Associated Virus In Vitro, Proc. Natl. Acad. Sci., USA,							
`		82:7096-7100 (1985)							
1 21	FB		tal., "Molecular Targets for AIDS Thera	py," Science, Vol. 249, pp. 1533-					
XW 1	,	1544 (1990)	,	, , , ,					
1	FC		al., "Rapid in Vitro Systems for Assessing	ng Activity of Agents Against					
KW-			V," AIDS: Modern Concepts and Therape						
-( -			Iarcel-Dekker, New York (1987)	,					
(1)	FD	Norbeck, D., e	t al., "A New 2',3'-Dideoxynucleoside Pro	ototype with In Vitro Activity					
KM,		Against HIV,"	Tetrahedron Lett., 30(46):6263-6266 (198	39)					
10.1	FE	Ohno, et al.,"Synthetic Studies on Biologically Active Natural Products by a							
KM 1		Chemicoenzymatic Approach," Tet. Letters, 40:145-152 (1984)							
(1)	FF	Okabe, M., et al., "Synthesis of the Dideoxynucleosides ddC and CNT from Glutamic							
KW .		Acid, Ribonolactone, and Pyrimidine Bases," J. Org. Chem., 53(20):4780-4786 (1988)							
	FG	Paff, et al., "Intracellular Metabolism of (-)- and (+)-cis-5-Fluoro-1-[2-							
1/1.1		Hydroxymethyl)-1,3-Oxathiolan-5-yl]Cytosine in HepG2 Derivative 2.2.15 (Subclone							
KW		P5A)Cells," Antimicrobial Agents and Chemotherapy, 1230-1238 (1994)							
•	FH		ochansky, "Chiral Stationary Phases for the Direct LC Separation of						
·W	,	Enantiomers," Advances in Chromatography, Giddings, J.C., Grushka, E., Brown, P.R.,							
( 7/3		eds.: Marcel Dekker: New York, 1987; Vol. 27, Chap. 3, pp. 73-127							
_	FI		., et al., "The Toxicity of Azidothymidine						
$\left[ \Lambda \right]$			AIDS and AIDS-Related Complex," N. Eng. J. Med., 317(4):192-197						
KM -		(1987)							
141	, FJ		, "Enzymic Resolution of cis- and trans-4-hydroxycyclopent-2-						
Kh &			" J. Chem Soc., Perkin Trans. 1, (10):2605-7 (1991)						
	, FK		Synthesis and Evaluation of 2-Pyridinone						
8/7/		Reverse Transcriptase Inhibitors, 2. Analogues of 3-Aminopyridin-2(1 <i>H</i> )-one," <i>J. Med.</i>							
40.		Chem., 35:3792-3802 (1992)							
VI	, FL		hi, S. et al., "The Synthesis of 1,3-Oxathic	plane-5-one Derivatives," Bull,					
th >	,	Chem. Soc. Japan, 45:913-915 (1972)							
101.0	FM		n-Nucleoside Inhibitors of HIV Reverse	Franscriptase: Screening					
KIN		Successes-Clinical Failures," Drug Design and Discovery, 8:255-263 (1992)							
15.	FN		F., et al., "Activities of the Four Optical Isomers of 2',3'-Dideoxy-3'-						
KIN.			BCH-189) against Human Immunodeficio						
( 0 /		Lymphocytes," Antimicrobial Agents and Chemotherapy 36(3):672-676 (1992)							
VI	," AIDS Research and Human								
EW!	FO	1	(6):963-990 (1992)	Ź					
Examiner:	1/	1.10-40	Date Considered:	1 100					
	本、	Mara	1 1/0	-190					
			whether or not citation is in conformance with MF						
not in confo	mance and	i not considere <b>ti</b> . Il	nclude copy of this form with next communication	to the applicant.					

Sheet 7 of 7

000000000000000000000000000000000000000	***************************************			Sneet 7 of 7				
Form PTO-	1449		Docket No.: EMU108DIV(1)	Application No. 08/488,097				
INFO	RMATION DI	ISCLOSURE	Applicant: Dennis C. Liotta, et al.					
***************************************	N AN APPLIC		Filing Date: June 7, 1995	Group Art Unit 1205				
		OTHER DOCU	MENTS (Including Author, Title, Date, Pertine	nt Pages, Etc.)				
	GA		., et al., "Pharmacokinetics and Metabolism					
KW.			acytidine in Rhesus Monkeys," Antimicrob					
4	GB	Schinazi, R.F.	., et al., "Selective Inhibition of Human Im	munodeficiency Viruses by				
111		Racemates an	d Enantiomers of cis-5-Fluoro-1-[2-(Hydro	oxymethyl)-1,3-Oxathiolan-5-				
40		yl]Cytosine,"	Antimicrobial Agents and Chemotherapy 36	5(11):2423-2431 (1992)				
1.6.1	GC	Schinazi, R.F.	., et al., "Substrate Specificity of Escherich	ia Coli Thymidine				
KIN		Phosphorylas	e for Pyrimidine Nucleoside with an Anti-F	Human Immunodeficiency Virus				
1 00		Activity," Bio	chemical Pharmacology 44(2):199-204 (199	92)				
,	GD		"Resolution of Racemic Carbocyclic Analo					
1K17 -			Action of Adenosine Deaminase Antiviral A					
12-12			ine Enantiomers," <i>J. Med. Chem.</i> , Vol. 30,					
	GE		L, "Affinity of the antiviral enantiomers of					
100	OL.		for human 2'-deoxycytidine kinase," <i>Biochem. Pharmacol.</i> , 45(7):1540-1543					
Kh		(1993)	of human 2 -deoxycytidine kinase, biochem. Fharmacol., 45(7):1540-1545					
<del>                                     </del>	GF		L., et al., "Synthesis and anti-HIV activity of	f soveral 2! fluore containing				
KW	Gr		•					
ļ			icleosides," J. Med. Chem., 33(8):2150-215					
1 1	GG	1 ' '	al., "The Resolution and Absolute Stereoch	-				
1 KM.		cis-1-[2-(Hydromethyl)-1,3-Oxathiolan-5-yl)cytosine (BCH189): Equipotent Anti-HIV						
			leosides & Nucleotides, 12(2):225-236 (1993					
ر) این ا	GH		al., "Solid State Conformation of Anti-Hum					
KM			s: Crystal Structures of Three 3'-Azido-3'-	deoxythymidine Analogues," J.				
<u> </u>			oc., 110:2277-2782 (1988)					
111/	GI		et al, "Nucleoside Synthesis with Trimethy	Isilyl Triflate and Perchlorate as				
LM			hem. Ber., 114:1234-1255 (1981)					
1 12	Ğ	1	"The 5'-Triphosphates of the (1) and (+) E					
I KM,			nethyl)-1,3-Oxathiolane-5-yl]Cytosine Equa					
`			iency Virus Type 1 Reverse Transcriptase,'	" Antimicrob. Agents and				
			7(8):1720-1722 (1993)					
1 .	GK		et al., "A General Method for Controlling					
K/Y		in the Synthes	sis of 2'-Deoxyribose Nucleosides," Tetrahe	dron Lett., 31(13):1815-1818				
` •		(1990)						
120	, GL		et al., "The Synthesis and Anti-HIV Activit	y of Pyrimidine Dioxolanyl				
~W~			Bioorganic & Medicinal Chemistry Letters,	•				
KM-	GM	L	L, "In vitro susceptibility of clinical isolates					
1 KM-	\		protease inhibitor," AIDS, 8:753-756 (1994	·				
121	GN '		al., "Cellular Metabolism of 3'-Azido-2',3"					
I KM>	<b>Y</b>		5'- O-Diphophoshexase Derivatives by Pre					
` ´			C'- Deoxyuridine Analogs," <i>Molecular Phar</i>					
	<del>-60</del> ~		cquired Immune Defictency Syndrome					
1	,	Volume 6 (1		-, (				
Examiner:	1/ /1	<del> </del>	Date Considered:	1-0				
	11.1	JONO	01 (02	98				
			whether or not citation is in conformance with MPE					
			clude copy of this form with next communication to					

\* Copy not provided